483
Glenmark Pharmaceuticals Inc USAFDA 483 - Glenmark Pharmaceuticals Inc USA - July 26, 2019
Record Details
An FDA inspection of Glenmark Pharmaceuticals Inc., USA in Monroe, NC, revealed a significant issue regarding the prevention of microbiological contamination in sterile drug products. The firm failed to establish procedures for the periodic re-certification of HEPA filters, which is critical for maintaining air quality in controlled environments. This deficiency could compromise the sterility of their drug products.
Open in Dashboard
ID · a0d148ad-00b7-4e0e-b4b8-7335fd1e7280